Cell, Gene Therapy Monitoring Guide Encouraging: Attorneys
Attorneys at Hyman, Phelps & McNamara say they are encouraged by an FDA draft guidance outlining a roadmap for postapproval monitoring of cell and gene therapies (CGT). Writing in the law firm’s online FDALawBlog, the attorneys acknowledge that FDA and industry are in the early stage of commercial CGT products and the unknowns surrounding long-term effects. Sponsors are encouraged to engage with the agency, implement robust IRB and informed consent processes, and prioritize patient safety. Over time, data from postapproval monitoring could inform whether long-term follow-up requirements might be adjusted or relaxed, they write.
The document, Postapproval Methods to Capture Safety and Efficacy Data for Cell and Gene Therapy Products, emphasizes that long-term follow-up is critical to understanding the durability of treatment benefits as well as risks such as delayed side effects, cancer, or mortality related to the therapy or underlying disease. FDA notes that pediatric patients present unique challenges, often requiring data collection into adulthood and new consent procedures as patients age.
The draft guidance reflects FDA’s intent to gather as much postmarket data as possible to better understand the transformative therapies, emphasizing that thorough planning, rigorous data collection, and close communication with CBER are essential to both patient safety and regulatory compliance, according to the attorneys
The guidance encourages sponsors to leverage existing data sources — electronic health records, claims data, registries, and vital statistics — to generate real-world evidence (RWE) supporting ongoing safety and effectiveness monitoring, the post notes. FDA underscores the importance of data quality, confidentiality, and compliance with HIPAA and Part 11 (electronic signatures) regulations. Sponsors are advised to engage the agency early when designing real-world (RWD)-based studies.
While RWD can support analyses of patient utilization, clinical outcomes, and background rates of adverse events, these sources were not designed for regulatory studies, according to the attorneys. The guidance highlights challenges such as incomplete data, inconsistent coding, fragmented patient records, and statistical limitations for rare diseases. Sponsors should perform feasibility assessments, link multiple data sources when possible, and address missing or unstructured data transparently, it says.
The post also points to registries that can provide longitudinal, structured data — including lab results, imaging, patient-reported outcomes, biomarkers, and adherence data — but may be affected by selection bias. FDA identifies four priority uses for registry-based monitoring: long-term durability of response, pediatric growth and development, malignancy surveillance, and fertility or pregnancy outcomes.
Additionally, the post notes that the guidance supports remote monitoring approaches — including telehealth, local clinics, and in-home assessments — to reduce administrative burden, expand patient access, improve retention, and enhance study generalizability. Protocols should clearly define safety and efficacy data collection, local provider roles, outcome documentation, and care for adverse events requiring urgent attention, it says.